Drug Profile
OP 145
Alternative Names: OP-145Latest Information Update: 01 Apr 2022
Price :
$50
*
At a glance
- Originator Leiden University
- Developer OctoPlus
- Class Peptide antibiotics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Otitis media
Most Recent Events
- 29 Mar 2022 GC Pharma is now called GC Biopharma
- 27 Feb 2013 OctoPlus has been acquired by Dr Reddys Laboratories
- 30 Nov 2010 OP 145 is available for licensing as of 30 Nov 2010. http://www.octoplus.nl